Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 3—March 2011


Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa

N. Sarita ShahComments to Author , Jessica Richardson, Prashini Moodley, Salona Moodley, Palav Babaria, Melissa Ramtahal, Scott K. Heysell, Xuan Li, Anthony P. Moll, Gerald Friedland, A. Willem Sturm, and Neel R. Gandhi
Author affiliations: Author affiliations: Tugela Ferry Care and Research Collaboration, Tugela Ferry, South Africa (N.S. Shah, J. Richardson, P. Babaria, S.K. Heysell, A.P. Moll, G. Friedland, N.R. Gandhi); Albert Einstein College of Medicine, Bronx, New York, USA (N.S. Shah, J. Richardson, X. Li, N.R. Gandhi); Montefiore Medical Center, Bronx (N.S. Shah, J. Richardson, X. Li, N.R. Gandhi); Nelson R. Mandela School of Medicine, Durban, South Africa (P. Moodley, S. Moodley, M. Ramtahal, A.W. Sturm); Yale University, New Haven, Connecticut, USA (P. Babaria, G. Friedland); Philanjalo Care Center, Tugela Ferry (A.P. Moll)

Main Article

Table 1

Drug susceptibility test results for 19 XDR TB patients, South Africa*

Drug resistance pattern (antibiogram) No. (%) patients
INH, RIF, EMB, SM, OFL, KM 2 (11)
INH, RIF, EMB, SM, OFL, KM, CAP 4 (21)
13 (68)
Total 19 (100)

*XDR TB, extensively drug-resistant tuberculosis; INH, isoniazid; RIF, rifampin; EMB, ethambutol; SM, streptomycin; OFL, ofloxacin; KM, kanamycin; CAP, capreomycin; ETO, ethionamide.

Main Article